Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
599.1 INR | -0.61% | +2.41% | +38.57% |
02-14 | Balaxi Pharmaceuticals Limited Incorporates New Wholly Owned Subsidiary in Chile | CI |
02-09 | Balaxi Pharmaceuticals Limited Announces Update on Company's Pharmaceutical Formulation Plant | CI |
Sales 2021 | 2.31B 27.73M 2.21B | Sales 2022 | 2.79B 33.49M 2.67B | Capitalization | 3.52B 42.14M 3.36B |
---|---|---|---|---|---|
Net income 2021 | 381M 4.57M 364M | Net income 2022 | 477M 5.72M 456M | EV / Sales 2021 | 2.28 x |
Net Debt 2021 | 19.9M 239K 19.01M | Net cash position 2022 | 37.39M 448K 35.72M | EV / Sales 2022 | 1.25 x |
P/E ratio 2021 |
13.8
x | P/E ratio 2022 |
7.38
x | Employees | 400 |
Yield 2021 * |
-
| Yield 2022 |
0.14% | Free-Float | 89.66% |
1 day | -0.61% | ||
1 week | +2.41% | ||
Current month | -2.03% | ||
1 month | +3.77% | ||
3 months | +37.68% | ||
6 months | +43.81% | ||
Current year | +38.57% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 27/09/42 | |
Director of Finance/CFO | - | 31/12/11 | |
Udayan Shukla
CMP | Compliance Officer | - | 10/10/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 27/09/42 | |
Founder | 51 | - | |
Director/Board Member | 42 | 03/05/17 |
Date | Price | Change | Volume |
---|---|---|---|
03/05/24 | 599.1 | -0.61% | 2,639 |
02/05/24 | 602.8 | -1.42% | 3,767 |
30/04/24 | 611.5 | +1.28% | 4,032 |
29/04/24 | 603.8 | +3.21% | 9,091 |
26/04/24 | 585 | +1.68% | 3,584 |
Delayed Quote NSE India S.E., May 03, 2024 at 12:43 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+38.57% | 72.98M | |
+14.23% | 69.5B | |
+7.11% | 8.2B | |
-20.55% | 7.97B | |
-4.06% | 7.84B | |
+2.26% | 4.66B | |
+17.12% | 4.32B | |
+1.41% | 4.19B | |
-3.02% | 3.89B | |
+21.42% | 3.62B |
- Stock Market
- Equities
- BALAXI Stock